SWITCH-2 (gesloten voor inclusie internationaal)
EudraCT 2011-004396-36 (gestopt in januari 2016)
Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)
Sorafenib followed by pazopanib versus pazopanib followed by sorafenib
IN: Patients with metastatic / advanced RCC (all histologies), who are not suitable for cytokine therapy and for whom study medication constitutes first-line treatment, MSKCC prognostic score (2004), low or intermediate, Subjects with at least one uni-dimensional (for RECIST 1.1) measurable lesion, Adequate bone marrow, liver and renal function. Ex: History of cardiac disease, Uncontrolled hypertension, Symptomatic metastatic brain or meningeal tumors, Patients with seizure disorder requiring medication, Any significant condition that increases the risk for bleeding, Known allergy to Votrient® or Nexavar®, Clinically significant gastrointestinal abnormalities De Switch II studie is gestopt in januari 2016.